Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.
Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.
复制标题
分子和功能成像在癌症靶向治疗中的应用现状和未来方向。
DOI：
10.1038/s41392-023-01366-y
复制
发表时间：
2023-02-27
影响因子：
39.3
通讯作者：
Zhang GJ
中科院分区：
文献类型：
--
作者：
Bai JW;Qiu SQ;Zhang GJ
靶向抗癌药物通过干扰对癌发生和肿瘤生长至关重要的特定信号通路来阻止癌细胞生长，而不是像细胞毒性化疗那样伤害所有快速分裂的细胞。实体瘤反应评估标准 (RECIST) 系统已用于通过卡尺、传统的基于解剖学的成像模式（如计算机断层扫描 (CT) 和磁共振成像 (MRI)）以及其他成像方法测量的目标病灶大小的变化来评估肿瘤对治疗的反应。然而，由于肿瘤大小与治疗引起的肿瘤坏死或缩小之间的相关性较差，RECIST在评估靶向治疗药物的疗效方面有时并不准确。当治疗确实使肿瘤尺寸减小时，这种方法也可能导致延迟识别反应。创新的分子成像技术在靶向治疗的黎明时代迅速变得重要，因为它们可以在细胞、亚细胞甚至分子水平而不是在解剖水平上可视化、表征和量化生物过程。这篇综述总结了不同的靶细胞信号传导途径、各种分子成像技术和开发的探针。此外，还系统地概述了分子成像在评估治疗反应和相关临床结果中的应用。未来应更加注重促进分子影像在评估生物相容性探针靶向治疗敏感性方面的临床转化。特别是，除了基于 RECIST 的方法外，还应开发结合先进人工智能的多模态成像技术，以全面、准确地评估癌症靶向治疗。
Targeted anticancer drugs block cancer cell growth by interfering with specific signaling pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing cells as in cytotoxic chemotherapy. The Response Evaluation Criteria in Solid Tumor (RECIST) system has been used to assess tumor response to therapy via changes in the size of target lesions as measured by calipers, conventional anatomically based imaging modalities such as computed tomography (CT), and magnetic resonance imaging (MRI), and other imaging methods. However, RECIST is sometimes inaccurate in assessing the efficacy of targeted therapy drugs because of the poor correlation between tumor size and treatment-induced tumor necrosis or shrinkage. This approach might also result in delayed identification of response when the therapy does confer a reduction in tumor size. Innovative molecular imaging techniques have rapidly gained importance in the dawning era of targeted therapy as they can visualize, characterize, and quantify biological processes at the cellular, subcellular, or even molecular level rather than at the anatomical level. This review summarizes different targeted cell signaling pathways, various molecular imaging techniques, and developed probes. Moreover, the application of molecular imaging for evaluating treatment response and related clinical outcome is also systematically outlined. In the future, more attention should be paid to promoting the clinical translation of molecular imaging in evaluating the sensitivity to targeted therapy with biocompatible probes. In particular, multimodal imaging technologies incorporating advanced artificial intelligence should be developed to comprehensively and accurately assess cancer-targeted therapy, in addition to RECIST-based methods.
登录
查看更多内容
影响因子：
3.7
作者：
Haagensen EJ;Thomas HD;Wilson I;Harnor SJ;Payne SL;Rennison T;Smith KM;Maxwell RJ;Newell DR
通讯作者：
Newell DR
DOI：
10.3390/diagnostics11081340
发表时间：
2021-07-26
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Chen BB;Shao YY;Lin ZZ;Hsu CH;Cheng AL;Hsu C;Liang PC;Shih TT
通讯作者：
Shih TT
影响因子：
7.9
作者：
Andronesi, Ovidiu C.;Esmaeili, Morteza;Batchelor, Tracy T.
通讯作者：
Batchelor, Tracy T.
影响因子：
9.3
作者：
Avallone, Antonio;Aloj, Luigi;Lastoria, Secondo
通讯作者：
Lastoria, Secondo
影响因子：
10.6
作者：
Beppu, Takaaki;Terasaki, Kazunori;Ogasawara, Kuniaki
通讯作者：
Ogasawara, Kuniaki